Bio-Thera Solutions has found a partner to help with US distribution of its proposed ustekinumab biosimilar, which entered phase 3 trial development this summer.
Guangzhou, China-based Bio-Thera Solutions has partnered with UK-based Hikma Pharmaceuticals for the commercialization of a proposed ustekinumab biosimilar (BAT2206) for the treatment of chronic inflammation.
BAT2206 references Stelara, which was developed by Janssen Biotech. In the United States, Stelara is approved for the treatment of psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Hikma would have rights for US commercialization of BAT2206 and first rights to negotiate marketing in the European Union. “This partnership provides us with a unique opportunity to enter the biosimilar market in the United States,” said Siggi Olafsson, CEO of Hikma.
In July 2021, Bio-Thera announced the first dosing of a patient in a phase 3 clinical study for BAT2206. The randomized, double-blind, parallel controlled study will compare the efficacy and safety of BAT2206 with Stelara in patients with moderate-to-severe psoriasis. Projected enrollment is 472 individuals in the United States and European Union.
Ustekinumab is a monoclonal antibody that suppresses the action of cytokines (interleukin 12/23) that contribute to the body’s inflammatory response.
Bio-Thera is developing biosimilars for bevacizumab (Avastin) and tocilizumab (Actemra), for the treatment of certain cancers and rheumatoid arthritis (RA), respectively. These pipeline products have completed phase 3 trials. The company is also developing golimumab (Simponi; RA), mepolizumab (Nucala; asthma), and dupilumab (Dupixent; asthma, eczema) biosimilars.
Hikma was founded in Jordan in 1978 and now has various FDA-inspected manufacturing sites globally. The company recently acquired Roxane Laboratories in Columbus, Ohio, in a move to build its non-injectables business.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.